Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
2023 · New England Journal of Medicine · 574 citations
https://doi.org/10.1056/nejmoa2304875
T
Thomas Winder
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
192
Papers
4.0K
Citations
34
h-index
75
i10-index
Thomas Winder is an academic researcher from University of Zurich. The author has contributed to research in topics: Colorectal Cancer Treatments and Studies & Genetic factors in colorectal cancer & Muscle Physiology and Disorders. The author has an h-index of 34, co-authored 164 publications.
ORCID: 0000-0002-4216-2994Papers by this author
worksRivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial
2018 · The Lancet Neurology · 177 citations
https://doi.org/10.1016/s1474-4422(18)30319-3
Mutation Update: The Spectra of Nebulin Variants and Associated Myopathies
2014 · Human Mutation · 139 citations
https://doi.org/10.1002/humu.22693
Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study
2018 · BMC Cancer · 36 citations
https://doi.org/10.1186/s12885-017-3967-0
A common variant of the MACC1 gene is significantly associated with overall survival in colorectal cancer patients
2012 · BMC Cancer · 31 citations
https://doi.org/10.1186/1471-2407-12-20
Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients
2014 · European Journal of Cancer · 31 citations
https://doi.org/10.1016/j.ejca.2014.05.007
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat